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Abstract
Background: The results of recent studies suggest the usefulness of PCT for early diagnosis of
neonatal sepsis, with varying results. The aim of this prospective multicenter study was to
determine the behavior of serum PCT concentrations in both uninfected and infected neonates,
and to assess the value of this marker for diagnosis of neonatal sepsis of vertical transmission.
Methods: PCT was measured in 827 blood samples collected prospectively from 317 neonates
admitted to 13 acute-care teaching hospitals in Spain over one year. Serum PCT concentrations
were determined by a specific immunoluminometric assay. The diagnostic efficacy of PCT at birth
and within 12–24 h and 36–48 h of life was evaluated calculating the sensitivity, specificity, and
likelihood ratio of positive and negative results.
Results: 169 asymptomatic newborns and 148 symptomatic newborns (confirmed vertical sepsis:
31, vertical clinical sepsis: 38, non-infectious diseases: 79) were studied. In asymptomatic neonates,
PCT values at 12–24 h were significantly higher than at birth and at 36–48 h of life. Resuscitation
at birth and chorioamnionitis were independently associated to PCT values. Neonates with
confirmed vertical sepsis showed significantly higher PCT values than those with clinical sepsis. PCT
thresholds for the diagnosis of sepsis were 0.55 ng/mL at birth (sensitivity 75.4%, specificity 72.3%);
4.7 ng/mL within 12–24 h of life (sensitivity 73.8%, specificity 80.8%); and 1.7 ng/mL within 36–48 h
of life (sensitivity 77.6%, specificity 79.2%).
Conclusion:  Serum PCT was moderately useful for the detection of sepsis of vertical
transmission, and its reliability as a maker of bacterial infection requires specific cutoff values for
each evaluation point over the first 48 h of life.
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Background
Neonatal sepsis of vertical transmission remains a major
problem associated with high morbidity and mortality in
newborns, particularly amongst preterm infants [1-4].
Rapid diagnosis is problematic because the first signs of
this disease may be minimal, and are similar to those of
various non-infectious processes; furthermore, bacterial
cultures are time-consuming, and other laboratory tests
are either not available for routine use or lack sensitivity
or specificity. In this situation, neonates with risk factors
for infection or clinical suspicion of infection are empiri-
cally treated with antibiotics. To avoid the unnecessary
treatment of uninfected patients, an early, sensitive and
specific laboratory test would be helpful to guide clini-
cians in neonatal units in deciding whether or not to start
administering antibiotics. Several leukocyte indices and
acute-phase protein levels have been evaluated for the
diagnosis of sepsis, and more recently, measurement of
multiple plasma cytokines [5] and leukocyte activation
markers [6] have showed promising results. However, to
date, no single laboratory test has provided rapid and reli-
able identification of early infected neonates. This inabil-
ity has led to a search for new diagnostic markers [7,8].
It has been recently reported that procalcitonin (PCT), the
prohormone of calcitonin, increases markedly in septic
conditions [9] and it appears to be a good predictor of
infection severity. Furthermore, the finding that PCT is
released into the circulation within 3 h after endotoxin
injection, plateaus at 6 h, and remains elevated for 24 h,
makes PCT a promising new agent for early and sensitive
identification of infected patients [10]. The results of
recent studies suggest the usefulness of PCT for early diag-
nosis of neonatal sepsis [11-23], although other investiga-
tors have observed lack of accuracy for this marker [24-
26]. Also, since markedly increased concentrations during
the first 48 h of life in newborn infants without bacterial
infection have been reported [12,23,27], there are con-
flicting data regarding what constitutes an abnormal
value.
The objective of this study was to determine the behavior
of serum PCT concentrations in uninfected and infected
neonates, and to assess the value of this marker for the
diagnosis of neonatal sepsis of vertical transmission.
Methods
Since 1995 the neonatal services of 28 acute-care teaching
hospitals distributed across 10 Autonomous Communi-
ties in Spain ("Grupo de Hospitales Castrillo") have been
involved in an ongoing prospective surveillance project to
assess the incidence and characteristics of infection of ver-
tical transmission during the newborn period. The neona-
tal services of 13 hospitals participated in the present
study. Between January 2000 and January 2001, all con-
secutive neonates within 48 h of life were prospectively
included in the study if blood samples were available for
timed PCT measurement according to three postnatal
periods: shortly after birth, within 12–24 h of life, and
within 36–48 h of age, and complete neonatal and out-
come data were collected to classify the newborn infant
into two distinct populations. Exclusion criteria were
infants born to mothers with gestational diabetes
(because available data indicate that PCT values are higher
for neonates born to diabetic mothers [12]) and refusal of
parental consent for blood sampling. The study was
approved by the Ethics Committees of the participating
hospitals and the parents gave their written informed con-
sent.
Two distinct populations were defined. The first popula-
tion (group 1) included a group of asymptomatic new-
born infants admitted during the first 24 h of life to the
neonatal unit because of prematurity, low birth weight, or
at least two risk factors for infection (table 1). They had no
clinical signs of sepsis during their first week of life and
had a negative blood culture. Patients in this group did
not receive antibiotic treatment. Those who were dis-
charged home before the seventh day of live were fol-
lowed to assure they did not develop late-onset vertical
sepsis.
The second population included symptomatic neonates
who were admitted to the neonatal unit and were evalu-
ated for sepsis during the first 48 h of life. Patients in this
population were later classified as group 2A (confirmed
vertical sepsis), group 2B (vertical clinical sepsis), or
group 2C (non-infectious disease). Criteria for confirmed
vertical neonatal sepsis and vertical clinical sepsis were
those previously established by "Grupo de Hospitales
Castrillo" [1,2]. Clinical signs of neonatal sepsis and risk
factors for vertical transmission are shown in Table 1.
- Group 2A: Confirmed vertical neonatal sepsis, defined as
at least three clinical signs of infection in association with
at least one bacteriological evidence of infection. Evidence
of infection included positive blood culture, at least three
positive surface swabs in the first 24 h of life for tradi-
tional pathogens of vertical transmission – such as group
B streptococci (GBS) and Escherichia coli-, or GBS culture-
positive mother).
- Group 2B: Vertical clinical sepsis, determined by at least
three clinical signs of infection, at least one laboratory
finding consistent with infection (leukocyte count
>30,000 cells/µL or <5,000 cells/µL, C-reactive protein >
12 mg/L), negative blood culture, and at least two risk fac-
tors for vertical transmission and/or intrapartum adminis-
tration of antibiotics.BMC Pediatrics 2007, 7:9 http://www.biomedcentral.com/1471-2431/7/9
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- Group 2C: Uninfected newborn infants with neonatal
pathology other than an infectious process and with neg-
ative blood culture.
PCT assay
Blood samples were centrifuged within 30 min of collec-
tion. Serum was stored at -20°C before analysis. PCT was
measured in duplicate by a specific immunoluminometric
assay (LUMItest®, Brahms Diagnostica GmbH, Berlin,
Germany), requiring 20 µL of serum and 2 h to complete.
The detection limit of this immunoluminometric assay is
0.08 ng/mL. Luminescence was measured automatically
on a Lumat LB 9507 tube luminometer (Berthold Tech-
nologies GmbH & Co. KG, Bad Wildbad, Germany).
Intraassay coefficients of variation were 5.9% at 31.0 ng/
mL and 13.8% at 0.81 ng/mL; interassay coefficients of
variation were 10.8% and 25.9% for the same PCT con-
centrations.
All PCT assays were performed by two centralised clinical
chemistry laboratories of two participating hospitals.
Statistical analysis
Statistical analysis was done with SPSS version 11.0 (SPSS
Inc., 2001, Chicago, Ill, USA) and EPIDAT version 3.0
(Servicio de Información sobre Saúde Pública de la Con-
sellería de Sanidade e Servicios Sociais de la Xunta de Gali-
cia, Spain, and the Health Situation Analysis Program of
the Pan American Health Organization, Washington D.C.,
USA). PCT values are expressed as median and interquar-
tile (25th–75th) ranges. Neither PCT values nor their log
transformation were normally distributed according to
kolmogorov-smirnov test, thus non-parametric tests were
used for comparisons between groups (Kruskal-Wallis test
and Mann-Whitney U test).
The association between different perinatal variables
(cesarean section, rupture of membranes more than 18 h
prior to delivery, clinical chorioamnionitis, resuscitation
at birth, and prenatal steroid exposure) and PCT values in
asymptomatic neonates was assessed with multiple linear
regression analysis. As PCT variable was not normally dis-
tributed, it was log-transformed and then extreme values
Table 1: Clinical signs of neonatal sepsis and risk factors for vertical transmission
Clinical signs Data
Respiratory Tachypnea (> 70 breaths/min in preterm babies, > 60 breaths/min in neonates at term)
Subcostal and/or intercostal retractions
Grunting
Apnea > 10 seconds
Haemodynamic Cyanosis
Pallor
Hypotension (blood pressure < 2 SD of the mean for age and weight)
Tachycardia (> 180 beats/min)
Bradichardia (< 100 beats/min in preterm babies, < 80 beats/min in neonates at term)
Digestive Rejection of food
Vomiting
Abdominal distention
Hepatomegaly
Poor peripheral perfusion
Haematological Anaemia (haemoglobin < 10 g/dL in preterm babies, < 11 g/dL in neonates at term)
Jaundice
Petechiae
Echymoses
Neurological Hypotony
Irritability
Letargy
Convulsions
Risk factors for infection Spontaneous premature delivery
Time of membrane rupture > 18 h
Intrapartum maternal fever > 38°C
Clinical chorioamnionitis (two of the following criteria: maternal fever, foetal tachycardia >140 bpm, purulent or foul-
smelling amniotic fluid, uterine tenderness)
Previous offspring with GBS infection
Maternal group B streptococci colonisation
Prenatal use of corticosteroidsBMC Pediatrics 2007, 7:9 http://www.biomedcentral.com/1471-2431/7/9
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were removed, so the variable showed adequate homoce-
dasticity for this analysis. In order to report the effect of
the perinatal variables, the regression coefficients and
95% confidence limits were exponentiated. R-square val-
ues were calculated to estimate how well the model
explained PCT variability.
The reliability of serum PCT concentration for the diagno-
sis of sepsis of vertical transmission was calculated by
receiver-operating characteristics (ROC) curves. Youden's
index (sensitivity + specificity - 1) was used for determina-
tion of optimal cutoff values of the diagnostic tests in the
different postnatal periods. Sensitivity, specificity, and the
likelihood ratio of positive and negative results with a
95% confidence interval (CI) were calculated. Statistical
significance was set at P < 0.05.
Results
The study included 827 blood samples collected from 317
neonates who met the inclusion criteria. Group 1
included 169 asymptomatic newborns. There were 148
symptomatic neonates distributed in group 2 as follows:
31 newborns with confirmed vertical sepsis (group 2A),
38 with vertical clinical sepsis (group 2B) and 79 in the
group of non-infectious diseases (group 2C). Non-infec-
tious diseases were all of respiratory origin (hyaline mem-
brane disease: 60, transient respiratory distress of the
newborn: 12, meconium aspiration syndrome: 5, pneu-
mothorax: 2). Causative pathogens of confirmed vertical
sepsis included GBS in 19 cases, E. coli in 8, Streptococcus
bovis in 1, Klebsiella oxytoca in 1, Haemophilus infuenzae in
1, and Candida albicans in 1. Clinical and anthropometric
characteristics are shown in Table 2. There were 2 deaths
in group 2A, no deaths in group 2B, and 3 deaths in group
2C. Patients in group 2C had significantly lower birth
weights and gestational ages (P < 0.0001, analysis of vari-
ance) than those in groups 1, 2A and 2B.
Pairwise comparisons of serum PCT concentrations in
group 1 at each postnatal period confirmed higher serum
PCT values (median [interquartile range]) at 12–24 h of
life (1.54 [0.68–3.78] ng/mL) than those at birth (0.35
[0.23–0.64] ng/mL, P < 0.0001, Mann-Whitney U test)
and at 36–48 h of life (0.73 [0.45–1.48] ng/mL, P  <
0.0001, Mann-Whitney U test) as shown in Figure 1.
Multiple linear regression analyses identified some varia-
bles independently associated to PCT values in group 1.
PCT concentrations were associated with resuscitation at
birth (defined as the necessity of tracheal intubation) at
36–48 h of life, and with chorioamnionitis at birth (Table
3). Nevertheless, variables specified in the model
accounted for just a small part of the PCT variability
(10.1% at birth, 2.0% at 12–24 h, and 9.4% at 36–48 h of
life).
Serum PCT concentrations of patients in groups 2A, 2B,
and 2C were higher than those of patients in group 1 at
each postnatal period, as showed in Table 4 (P < 0.0001,
Mann-Whitney U test). Patients of group 2A (confirmed
vertical sepsis) had consistently higher serum PCT values
than those of group 2B (vertical clinical sepsis) at birth (P
= 0.006), at 12–24 h (P = 0.002), and 36–48 h of life (P =
0.032). There were no significative differences between
the PCT concentrations of neonates with respiratory dis-
eases (group 2C) and those with clinical sepsis.
We elaborated ROC curves considering groups 2A and 2B
as infected and group 1 as non-infected. ROC of PCT at
birth and 12–24 h and 36–48 h of life for the diagnosis of
sepsis of vertical transmission are shown in Figure 2. The
areas under the ROC curve for the three periods were
0.754 (95% CI, 0.671 to 0.838), 0.802 (95% CI, 0.735 to
0.869), and 0.820 (95% CI, 0.750 to 0.891), respectively.
Cutoff levels with the optimum diagnostic efficiency
derived from the ROC curves were ≥ 0.55 ng/mL at birth
Table 2: Obstetric history and somatometric characteristics of patients included in the study
Group 1 Group 2A Group 2B Group 2C
No. patients 169 31 38 79
Gestational age, weeks, mean (SD) 36.2 (3.7) 34.5 (5.4) 35.2 (4.8) 30.3 (6.2)
Weight at birth, g., mean (SD) 2622 (860) 2496 (1107) 2573 (997) 1542 (880)
GBS colonisation, no. (%) 44 (26.0) 13 (41.9) 0 (0) 11 (13.9)
Prenatal steroid exposure, no. (%) 40 (23.7) 9 (29.0) 9 (23.7) 38 (48.1)
Membrane rupture > 18 h, no. (%) 70 (41.4) 18 (22.8) 5 (13.2) 11 (35.5)
Intrapartum fever, no. (%) 15 (8.9) 7 (22.6) 8 (21.1) 3 (3.8)
Chorioamnionitis, no. (%) 10 (5.9) 4 (12.9) 3 (7.9) 8 (10.1)
Intrapartum antibiotics, no. (%) 105 (62.1) 15 (48.4) 12 (31.6) 22 (27.8)
Resuscitation at birth, no. (%) 10 (5.9) 8 (25.8) 8 (21.1) 33 (41.8)
Males, no. (%) 93 (55.0) 15 (48.4) 16 (42.1) 43 (54.4)
Group 1: asymptomatic newborn infants; group 2A: confirmed vertical neonatal sepsis; group 2B: vertical clinical sepsis; group 2C: neonatal 
pathology other than an infectious process (respiratory diseases).BMC Pediatrics 2007, 7:9 http://www.biomedcentral.com/1471-2431/7/9
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(sensitivity 75.4%, specificity 72.3%), ≥ 4.7 ng/mL at 12–
24 h of life (sensitivity 73.8%, specificity 80.8%), and ≥
1.7 ng/mL at 36–48 h of life (sensitivity 77.6%, specificity
79.2%) (Table 5). We also selected other cutoff points in
order to get better sensitivity (>90%) as seen in Table 6.
Discussion
This study shows that increased serum PCT concentra-
tions in newborn infants are related to different factors
other than neonatal sepsis. Elevated PCT levels were
apparent 12–24 h after birth in asymptomatic uninfected
infants. The physiological peak of serum PCT concentra-
tions in healthy neonates has been previously reported
[12,23], and increased PCT concentrations have also been
found in neonates with very low probability of infection
[27,28]. Although PCT may cross the placental barrier, the
findings of higher PCT concentrations in cord sera com-
pared with maternal samples, with even larger differences
at 24 and 48 h of age, cannot be explained on the grounds
of maternal transfer alone; therefore, the postnatal surge
of PCT most likely represents endogenous synthesis [29].
This phenomenon might be attributed to direct stress on
the baby during the perinatal period or to the adaptation
to the extrauterine environment. The normal birth process
and the extrauterine adaptation stimulates an acute phase
reaction in the newborn infant with a release of C-reactive
protein (CRP), interleukin-6 (IL-6), and serum amyloid A
[30,31].
The higher concentrations of PCT observed in uninfected
infants with respiratory disorders (mostly hyaline mem-
brane disease) compared with asymptomatic infants is
also consistent with previous reports. Other authors have
shown elevated PCT values during the first 10 days of life
in uninfected newborns who presented respiratory dis-
tress syndrome (RDS) [26,32]. Because no significant
effect related to the severity of RDS could be detected,
Monneret et al. [32] suggested that hypoxemia (a com-
mon event to each etiology of RDS and which is transient
during delivery) could be responsible for these increased
PCT values, providing further support for the hypothesis
of pulmonary PCT synthesis. Yet it is not possible to
assure these patients were really uninfected, since evi-
dence of no infection was based on negative bacterial cul-
tures, absence of fever, and a normal CRP value, and these
criteria may fail in an appreciable number of cases [33].
Our study has a similar problem, as intrapartum antibiot-
ics had been used in 22/79 neonates with respiratory dis-
orders, and 66/79 were treated with antibiotics after birth.
This is also the reason why we excluded group 2C from
ROC curves.
Elevated PCT levels in newborn infants who required
resuscitation at birth may be related to the stressful situa-
tion or tissular hypoxia. Similar findings have been
Table 3: Independent effects of some perinatal variables on serum procalcitonin values at birth, at 12–24 h and 36–48 h of life.
Risk factor Serum PCT values, ng/mL, median (interquartile 25th–75th range)
At birth 12–24 h of life 36–48 h of life
Cesarean section 1.08 (0.58–2.02) 0.73 (0.26–2.02) 0.91 (0.54–1.51)
Membrane rupture > 18 h 0.67 (0.37–1.20) 1.32 (0.51–3.45) 0.96 (0.59–1.56)
Chorioamnionitis 18.61 (2.43–142.5)* 1.08 (0.14–8.15) 1.78 (0.54–5.84)
Resuscitation at birth 1.30 (0.39–4.40) 5.58 (0.49–63.17) 8.71 (2.40–31.57)*
Prenatal steroid exposure 1.84 (0.91–3.73) 0.58 (0.17–1.95) 0.93 (0.49–1.76)
Includes data of 169 asymptomatic newborns (group 1). Data are expressed as regression coefficients (95% confidence interval).
* P < 0.01.
Changes in PCT from birth to 48 h of life in asymptomatic  newborns Figure 1
Changes in PCT from birth to 48 h of life in asympto-
matic newborns. Box plot comparing serum PCT concen-
trations in asymptomatic newborns (group 1) at birth, at 12–
24 h and 36–48 h of life. The boxes are limited by the 75th 
and 25th percentiles of the data. The middle lines represent 
the median. Values plotted with cross markers are outside 
values (more than 1.5 times the interquartile range over 75th 
or under 25th percentiles). Values plotter with plus markers 
are far out values (more than 3 times the interquartile range 
over 75th or under 25th percentiles).
Birth 12-24 h 36-48 h
1000
100
10
1
0.1
0.01
Procalcitonin
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Table 6: Performance of procalcitonin at birth, at 12–24 h, and 36–48 h of life for the diagnosis of neonatal sepsis of vertical 
transmission (cutoff points selected to achieve 90% sensitivity).
At birth n = 205 12–24 h of life n = 212 36–48 h of life n = 193
Cutoff, ng/ml ≥0.15 ≥1.2 ≥0.75
Sensitivity, % (95% CI) 91.2 (81.1 – 96.2) 90.2 (80.2 – 95.4) 91.8 (80.8 – 96.8%)
Specificity (95% CI) 10.8 (6.8 – 16.8) 43.0 (35.4 – 51.0) 51.4 (43.3 – 59.4)
Youden's index 0.02 0.33 0.43
PPV (95% CI) 28.3 (22.3 – 35.2) 39.0 (31.3 – 47.2) 55.9 (44.1 – 67.1)
NPV (95% CI) 76.2 (54.9 – 89.4) 91.5 (82.8 – 96.1) 91.2 (84.9 – 95.0)
LR+ (95% CI) 1.02 (0.93 – 1.13) 1.58 (1.35 – 1.86) 1.89 (1.57 – 2.28)
LR- (95% CI) 0.81 (0.32 – 2.07) 0.23 (0.10–0.50) 0.16 (0.06 – 0.41)
PPV: positive predictive value, NPV: negative predictive value, LR+: likelihood ratio of a positive result, LR-: likelihood ratio of a negative result.
Table 4: Serum procalcitonin values at birth, at 12–24 h and 36–48 h of life in the groups included in the study.
Study group Serum PCT values, ng/mL median (interquartile 25th–75th range)
At birth 12–24 h of life 36–48 h of life
Group 1, n = 169 0.35 (0.23–0.64) 1.54 (0.68–3.78) 0.73 (0.45–1.48)
Group 2A, n = 31 13.59 (0.50–101.3) 30.65 (6.38–95.9) 6.74 (2.85–29.15)
Group 2B, n = 38 1.09 (0.54–3.04) 5.88 (1.53–11.92) 2.52 (1.44–8.71)
Group 2C, n = 79 1.12 (0.38–7.06) 4.79 (1.22–16.89) 2.96 (0.97–7.11)
Group 1: asymptomatic newborn; group 2A: confirmed vertical neonatal sepsis; group 2B: vertical clinical sepsis; group 2C: neonatal pathology 
other than an infectious process (respiratory diseases).
Table 5: Performance of procalcitonin at birth, at 12–24 h, and 36–48 h of life for the diagnosis of neonatal sepsis of vertical 
transmission (cutoff points selected according to Youden's index).
At birth n = 205 12–24 h of life n = 212 36–48 h of life n = 193
Cutoff, ng/ml ≥0.55 ≥4.7 ≥1.7
Sensitivity, % (95% CI) 75.4 (62.9 – 84.8) 73.8 (61.6 – 83.2) 77.6 (64.1 – 87.0%)
Specificity (95% CI) 72.3 (64.6 – 78.9) 80.8 (73.8 – 86.3) 79.2 (71.8 – 85.0)
Youden's index 0.48 0.55 0.57
PPV (95% CI) 51.2 (40.7 – 61.6) 60.8 (49.4 – 71.1) 55.9 (44.1 – 67.1)
NPV (95% CI) 88.4 (81.5 – 93.0) 88.4 (82.0 – 92.7) 91.2 (84.9 – 95.0)
LR+ (95% CI) 2.72 (2.02 – 3.67) 3.84 (2.68 – 5.50) 3.72 (2.62 – 5.29)
LR- (95% CI) 0.34 (0.21 – 0.55) 0.32 (0.21–0.50) 0.28 (0.17 – 0.48)
PPV: positive predictive value, NPV: negative predictive value, LR+: likelihood ratio of a positive result, LR-: likelihood ratio of a negative result.BMC Pediatrics 2007, 7:9 http://www.biomedcentral.com/1471-2431/7/9
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reported in perinatal asphyxia [32] and need for delivery
room intubation [13]. Chorioamnionitis has been also
independently associated with increased PCT values [13].
These findings in our study must be considered cau-
tiously, since variables selected for the multiple linear
regression analysis explained just a small piece of total
PCT variability. It is noteworthy that we found no effect of
perinatal variables on PCT at 12–24 h of life, when PCT
values were higher.
In this study, serum PCT concentrations showed a moder-
ate diagnostic efficiency in the detection of sepsis of verti-
cal transmission. When considering a potentially serious
illness as neonatal sepsis, the selection of cutoff values for
a diagnostic marker must emphasize sensitivity over spe-
cificity [34]. But with our ROC curves, improvements in
sensitivity implied big reductions in specificity, and the
overall efficacy was quite better using Youden's index to
select the cutoff points (Tables 5 and 6). Specific cutoff
values for each evaluation point over the first 48 h of life
were needed to improve the diagnostic accuracy of this
marker of bacterial infection. In 1998, Chiesa et al. [12]
determined reference ranges for PCT across the range of
postnatal hours from 0 to 48 h and, in a further study,
these authors showed that PCT sensitivity and specificity
were greater than those of CRP or interleukin 6 if different
cutoff points at birth and at 24 h and 48 h of life were used
[13]. The sensitivity and specificity values found in our
study according to specific cutoff points for each evalua-
tion point over the first 48 h of life are within the range of
57–100% sensitivity and 50–100% specificity previously
reported for thresholds ranging between 0.5 and 100 ng/
mL [9,11-17,24-26]. The heterogeneity in the study
design, particularly the definition of sepsis, and the differ-
ent nature of the control groups might explain the differ-
ences in sensitivity and specificity. Neonatal sepsis of
vertical transmission was diagnosed according to criteria
defined by our group for infections diagnosed within the
first 3 days after delivery [1,2]. However, the present
results refer to early-onset neonatal sepsis because the
study population was limited to neonates within 48 h of
life.
A limitation of this study is that the reliability of PCT was
not compared with CRP or other infection markers, such
the leukocyte count, because these analyses were not
standardised and performed at every biochemical labora-
tory of the participating hospitals. Some studies have
shown that PCT is more reliable than CRP as a test for the
diagnosis of early-onset neonatal sepsis [13-15], but other
studies have not found any advantage of PCT over CRP
[11,23-25]. However, it is important to consider that large
sample sizes are needed to assess differences in the accu-
racy of diagnostic tests, e.g., according to an estimated
25% prevalence of sepsis and an absolute difference of
15% between sensitivities of PCT and CRP, approximately
300 patients would be needed for 80% statistical power.
Another limitation of our study is that we used a control
group formed by asymptomatic infants without evidence
of infection, which may overestimate the reliability of
PCT as diagnostic test when used in a population of
neonates with clinical suspicion of sepsis [35].
To be able to establish precise conclusions regarding the
usefulness of PCT and other inflammatory response mark-
ers, some methodological issues should be solved [36],
specially regarding a sufficiently reliable "gold standard"
of neonatal sepsis. Although a recent international con-
sensus conference has adapted diagnostic criteria for sep-
sis to several pediatric age groups, including newborn
infants, premature infants were not included [37]; so
these criteria for sepsis must be evaluated before being
used in the neonatal intensive care unit. On the other side,
although, in the field of neonatology, the concept of "clin-
ical sepsis" is widely used, a uniform definition of this
common diagnosis is lacking, as is a standard criterion for
the inclusion or exclusion of probable/suspected sepsis
from the analysis [38]. Moreover, the risk of neonatal sep-
sis is likely to be different with varying scenarios related to
the neonatal population [7]. An optimal design of these
studies should allow assessing the pre-test probability of
ROC curves Figure 2
ROC curves. ROC curves of PCT at birth, and at 12–24 h 
and 36–48 h of life for the diagnosis of neonatal sepsis of ver-
tical transmission.
1,0
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sepsis according to different clinical features and risk fac-
tors for infection.
Conclusion
We conclude that the serum PCT concentration showed a
moderate diagnostic value for the detection of sepsis of
vertical transmission, with better results after 12 h of
birth. The reliability of PCT as a maker of bacterial infec-
tion requires specific cutoff values for each evaluation
time point beyond the first 48 h of life.
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